Q-omics provides the consensus-scored MOGAT3 profile across patient tissues and cancer cell-line models. MOGAT3 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MOGAT3 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, MOGAT3 RNA expression shows 12,325 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KICH, KIRC, and TGCT as cancer lineages where MOGAT3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MOGAT3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MOGAT3 survival associations across molecular data types. MOGAT3 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MOGAT3 RNA expression–survival associations across cancer types. High MOGAT3 expression shows unfavorable associations in KICH, ACC and PAAD, but favorable associations in KIRP, READ and KIRC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for MOGAT3 RNA expression.
This table summarizes MOGAT3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MOGAT3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MOGAT3 shows lower tumor expression in KICH, CHOL and COAD and higher tumor expression in KIRC, STAD and BLCA. The KIRC box plot shows higher MOGAT3 RNA expression in tumor versus normal tissue (log2 FC = +1.599, t-test p < 0.001).
This table shows molecular features associated with MOGAT3 in patient tissues and cancer cell lines. In patient samples, MOGAT3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MOGAT3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LARGE_INTESTINE.
